


Serial No. 09/868,395  
 Attorney Docket No. PG3612USw

**Amendments to the Claims:**

Please amend the claims as follows:

Claims 1-28 (Cancelled)

Claim 29 (Currently amended): A compound of formula I:



wherein R<sup>1</sup> and R<sup>2</sup> independently represent

- (i) -C<sub>1-6</sub> alkyl, -C<sub>3-8</sub> cycloalkyl or -C<sub>1-3</sub> alkylC<sub>3-8</sub> cycloalkyl,  
 or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or -OC<sub>1-6</sub>alkyl groups;
- (ii) -(CH<sub>2</sub>)<sub>n</sub>Ar<sup>1</sup> or -(CH<sub>2</sub>)<sub>n</sub>OAr<sup>1</sup>;  
 or NR<sup>1</sup>R<sup>2</sup> together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more -(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>n</sub>Ar<sup>1</sup>, -(CO)<sub>n</sub>C<sub>1-6</sub>alkylAr<sup>1</sup>Ar<sup>2</sup>, -(CO)<sub>n</sub>C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>n</sub>OH, -(CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>n</sub>OH, -(CH<sub>2</sub>)<sub>n</sub>OC<sub>1-6</sub>alkyl, -O(CH<sub>2</sub>)<sub>n</sub>Ar<sup>1</sup>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>Ar<sup>1</sup>, piperidin-1-yl, -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>8</sup>R<sup>9</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>n</sub>Ar<sup>1</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-3</sub>alkylC<sub>3-6</sub>cycloalkyl, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-6</sub>alkyldiC<sub>3-6</sub>cycloalkyl, -CONR<sup>10</sup>(CH<sub>2</sub>)<sub>n</sub>Ar<sup>1</sup>, halogen, -NHSO<sub>2</sub>C<sub>1-6</sub>alkyl, -SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, -SO<sub>2</sub>C<sub>1-6</sub>alkyl or -SO<sub>2</sub>Ar<sup>2</sup> groups;
- R<sup>3</sup> represents -C<sub>1-6</sub>alkylNHC(=NH)NH<sub>2</sub>, -C<sub>2-6</sub>alkenylNHC(=NH)NH<sub>2</sub>, -C<sub>2-6</sub>alkynylNHC(=NH)NH<sub>2</sub>, -C<sub>1-6</sub>alkylNR<sup>14</sup>R<sup>18</sup>, -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>14</sup>R<sup>18</sup>, -(CH<sub>2</sub>)<sub>n</sub>COC<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>n</sub>CHNR<sup>18</sup>CONR<sup>20</sup>R<sup>21</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>18</sup>CONR<sup>14</sup>R<sup>18</sup>, -(CH<sub>2</sub>)<sub>d</sub>NR<sup>18</sup>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>d</sub>CONR<sup>18</sup>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>d</sub>COOR<sup>18</sup>, -(CH<sub>2</sub>)<sub>d</sub>Ar<sup>3</sup>, -O(CH<sub>2</sub>)<sub>d</sub>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>d</sub>CO(CH<sub>2</sub>)<sub>d</sub>Ar<sup>3</sup> or -(CH<sub>2</sub>)<sub>d</sub>OAr<sup>3</sup>;
- or R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>c</sub>-2,4-imidazolidinedione, -(CH<sub>2</sub>)<sub>c</sub>(piperidin-4-yl), -(CH<sub>2</sub>)<sub>c</sub>(piperidin-3-yl), -(CH<sub>2</sub>)<sub>c</sub>(piperidin-2-yl), -(CH<sub>2</sub>)<sub>c</sub>(morpholin-3-yl) or -(CH<sub>2</sub>)<sub>c</sub>(morpholin-2-yl) optionally substituted on nitrogen by -(CO)fC<sub>1-6</sub>alkyl,

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

$-(CO)_f(CH_2)_gAr^2$  or  $-C(=NH)NH_2$ ;

or  $R^3$  represents  $-(CH_2)_z$  dibenzofuran optionally substituted by  $-C_{1-6}$ alkyl or halogen;

or  $R^3$  represents  $-(CH_2)_c$  thioxanthene-9-one;

$R^4$  represents hydrogen,  $-C_{1-6}$  alkyl,  $-C_{1-3}$  alkyl $C_{3-6}$  cycloalkyl,  $-(CH_2)_qAr^2$ ,  $-C_{1-4}$ alkyl- $X-R^7$ ,  $-C_{1-4}$ alkyl  $SO_2C_{1-4}$  alkyl,  $-C_{1-6}$ alkyl $NR^{12}R^{13}$  or  $-C_{1-6}$  alkyl $NR^{12}COC_{1-6}$  alkyl;

$R^5$  represents hydrogen, or  $R^4R^5$  together with the carbon to which they are attached form a  $C_{5-7}$  cycloalkyl ring;

$R^6$  represents hydrogen or  $-C_{1-6}$  alkyl, or  $R^6$  and  $R^4$  together with the N and C atoms to which they are respectively attached form a pyrrolidine ring;

$R^7$  represents hydrogen,  $-(CH_2)_wNR^{12}R^{13}$ ,  $-(CH_2)_uAr^2$  or  $-(CH_2)_wNR^{12}COC_{1-6}$  alkyl;

$R^8$ ,  $R^9$ ,  $R^{16}$  and  $R^{17}$  independently represent hydrogen,  $-C_{1-6}$ alkyl,  $-C_{3-6}$ cycloalkyl,  $-C_{1-3}$ alkyl $C_{3-6}$  cycloalkyl,  $-C_{2-6}$ alkenyl or  $NR^8R^9$  or  $NR^{16}R^{17}$  together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by  $-C_{1-6}$  alkyl,  $-COphenyl$  or  $-SO_2methyl$ ;

$R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{15}$ ,  $R^{18}$ ,  $R^{20}$  and  $R^{21}$  independently represent hydrogen or  $-C_{1-6}$ alkyl;

$R^{14}$ ,  $R^{19}$  and  $R^{22}$  independently represent hydrogen,  $-C_{1-6}$ alkyl,  $-C_{3-6}$ cycloalkyl or  $-(CH_2)_xAr^4$  or  $NR^{14}R^{18}$  or  $NR^{15}R^{22}$  together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or N- $C_{1-6}$ alkylpiperazinyl;

$Ar^1$  represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen,  $-C_{1-6}$ alkyl,  $Ar^1$ , hydroxy,  $-OC_{1-6}$ alkyl,  $-CF_3$ , nitro,  $-Ar^2$  or  $-OAr^2$  groups;

$Ar^2$  represents phenyl optionally substituted by one or more halogen,  $-C_{1-6}$ alkyl, hydroxy,  $-OC_{1-6}$ alkyl,  $-CF_3$  or nitro groups;

$Ar^3$  represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more  $-CO(CH_2)_gAr^4$ ,  $-(CH_2)_yAr^4$ ,  $-(CH_2)_yCOAr^4$ ,  $-(CO)_aC_{1-6}$  alkyl,  $-(CO)_aC_{2-6}$  alkenyl,  $-(CO)_aC_{2-6}$  alkynyl,  $-(CO)_aC_{3-8}$ cycloalkyl,  $-(CO)_aC_{1-6}$ haloalkyl, halogen,  $-COCH_2CN$ ,  $-(CH_2)_bNR^{16}R^{17}$ ,  $-(CH_2)_bNHC(=NH)NH_2$ ,  $-CYNR^{16}(CO)_aR^{17}$ ,  $-(CH_2)_bNR^{15}COR^{19}$ ,  $-(CH_2)_bCONR^{15}R^{22}$ ,  $-(CH_2)_bNR^{15}CONR^{15}R^{22}$ ,  $-(CH_2)_bCONR^{15}(CH_2)_bNR^{15}R^{22}$ ,  $-(CH_2)_bSO_2NR^{15}R^{22}$ ,  $-(CH_2)_bSO_2NR^{15}COAr^2$ ,  $-(CH_2)_bNR^{15}SO_2R^{19}$ ,  $-SO_2R^{19}$ ,  $-SOR^{19}$ ,  $-(CH_2)_zOH$ ,

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

-COOR<sup>15</sup>, -CHO, -OC<sub>1-10</sub>alkyl, -O(CH<sub>2</sub>)<sub>j</sub>NR<sup>15</sup>R<sup>22</sup>, -O(CH<sub>2</sub>)<sub>j</sub>NHC(=NH)NH<sub>2</sub>, -O(CH<sub>2</sub>)<sub>b</sub>CONR<sup>16</sup>R<sup>17</sup>, -O(CH<sub>2</sub>)<sub>k</sub>COOR<sup>15</sup>, -O(CH<sub>2</sub>)<sub>j</sub>OAr<sup>2</sup>, -O(CH<sub>2</sub>)<sub>b</sub>Ar<sup>2</sup>, 3-phenyl-2-pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

Ar<sup>4</sup> represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, -C<sub>1-6</sub>alkyl, hydroxy, -OC<sub>1-6</sub>alkyl, -CF<sub>3</sub>, nitro or -CONH<sub>2</sub> groups;

X and Y independently represent O or S;

a, f, k, s and n independently represent 0 or 1;

b, c, r, x, y and z independently represent an integer 0 to 2;

d, g and u independently represent 1 or 2;

e, h, q and w independently represent an integer 1 to 3;

j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4;

t independently represents an integer 0 to 3;

and or salts and or solvates thereof.

Claim 30 (Previously presented): A compound according to claim 29 wherein R<sup>4</sup> represents -C<sub>1-6</sub>alkyl, R<sup>5</sup> represents hydrogen or R<sup>4</sup>R<sup>5</sup>, together with the carbon to which they are attached, forms a cyclohexyl ring, and R<sup>6</sup> represents hydrogen or methyl.

Claim 31 (Previously presented): A compound according to claim 30 wherein R<sup>4</sup> represents -C<sub>1-6</sub>alkyl and R<sup>5</sup> and R<sup>6</sup> represent hydrogen.

Claim 32 (Previously presented): A compound according to claim 31 wherein R<sup>4</sup> represents -CH<sub>2</sub>CHMe<sub>2</sub> and R<sup>5</sup> and R<sup>6</sup> represent hydrogen.

Claim 33 (Previously presented): A compound according to claim 29 wherein NR<sup>1</sup>R<sup>2</sup> together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-tetrahydroisoquinoline optionally substituted by a -(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>r</sub>Ar<sup>1</sup>, -(CO)<sub>n</sub>C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>s</sub>CONR<sup>8</sup>R<sup>9</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>r</sub>Ar<sup>1</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-3</sub>alkylC<sub>3-6</sub>cycloalkyl, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-6</sub>alkyldiC<sub>3-6</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>s</sub>OC<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>s</sub>O(CH<sub>2</sub>)<sub>p</sub>OH, piperidin-1-yl, -(CH<sub>2</sub>)<sub>s</sub>OH or -CONR<sup>10</sup>(CH<sub>2</sub>)<sub>r</sub>Ar<sup>1</sup> group.

Serial No. 09/868,395  
 Attorney Docket No. PG3612USw


**Claim 34 (Previously presented):** A compound according to claim 33 wherein NR<sup>1</sup>R<sup>2</sup> together represents morpholinyl or piperazinyl optionally N-substituted by -(CO)<sub>n</sub>C<sub>1-6</sub> alkyl, piperazinyl N-substituted by -(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>2</sub>Ar<sup>1</sup>, piperidinyl substituted by -NR<sup>10</sup>(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>2</sub>Ar<sup>1</sup> or piperidinyl substituted by -(CH<sub>2</sub>)<sub>2</sub>CONR<sup>8</sup>R<sup>9</sup>.

**Claim 35 (Previously presented):** A compound according to claim 29 wherein R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>2</sub>-2,4-imidazolidinedione-3-yl, -(CH<sub>2</sub>)<sub>2</sub>-thioxanthan-9-one-3-yl, -(CH<sub>2</sub>)<sub>2</sub>Ar<sup>3</sup>, -O(CH<sub>2</sub>)<sub>2</sub>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>2</sub>OAr<sup>3</sup> or -(CH<sub>2</sub>)<sub>2</sub>dibenzofuran.

**Claim 36 (Previously presented):** A compound according to claim 35 wherein R<sup>3</sup> represents -OCH<sub>2</sub>Ar<sup>3</sup>, -CH<sub>2</sub>OAr<sup>3</sup> or dibenzofuran.

**Claim 37 (Previously presented):** A compound according to claim 36 wherein R<sup>3</sup> represents -CH<sub>2</sub>OAr<sup>3</sup>.

**Claim 38 (Currently amended):** A compound according to claim 29 wherein R<sup>4</sup> and R<sup>5</sup> have the stereochemical orientation shown in formula (Ia):



**Claim 39 (Currently amended):** A compound selected from the group consisting of formula (I) which is:

(2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

(2S)-2-{{(2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl}amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-((2-methylphenoxy)acetyl)amino) pentanoyl]amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-{{(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-{{(2S)-2-((1-Bromo-2-naphthyl)oxy)acetyl}amino}-4-methylpentanoyl]amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]propanoic acid;

(2S)-2-{{(2S)-2-((2-[2-(Tert-butyl)phenoxy]acetyl)amino)-4-methyl pentanoyl}amino}-3-[4-{{(4-((4-fluorobenzyl)amino)carbonyl)-1-piperidinyl} carbonyl}oxy]phenyl]propanoic acid;

(2S)-2-[[2-(2,4-Dichlorophenoxy)acetyl]amino]-4-methyl pentanoyl]amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[[2-(2-Benzoylphenoxy)acetyl]amino]-4-methyl pentanoyl]amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[[2-(2-propylphenoxy)acetyl]amino) pentanoyl]amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-{{(2S)-2-((1-Bromo-2-naphthyl)oxy)acetyl}amino}-4-methylpentanoyl]amino}-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-2-[[2-(Benzyoxy)carbonyl]amino]-4-methylpentanoyl]amino]-3-[4-[(4-morpholinylcarbonyl)oxy]phenyl]propanoic acid;

(2S)-3-[4-({[4-(2-Furoyl)-1-piperazinyl]carbonyl}oxy)phenyl]-2-[[2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl]amino]propanoic acid;

(2S)-2-[[2-(2-Cyclohexylphenoxy)acetyl]amino]-4-methyl pentanoyl]amino]-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

(2S)-2-{{(2S)-2-((1-Bromo-2-naphthyl)oxy)acetyl}amino)-4-methyl pentanoyl]amino}-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

(2S)-3-(4-{{(4-({[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)-2-[(2S)-2-{{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methylpentanoyl}amino]propanoic acid;  
(2S)-2-[(2S)-2-{{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl}amino]-3-(4-{{(4-({[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)propanoic acid;  
(2S)-3-(4-{{(4-({[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)-2-[(2S)-2-{{[2-(2-iodophenoxy)acetyl]amino}-4-methyl pentanoyl}amino]propanoic acid;  
(2S)-2-{{(2S)-2-{{[2-[2-(Tert-butyl)phenoxy]acetyl]amino}-4-methyl pentanoyl}amino}-3-(4-{{(4-({[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)propanoic acid;  
(2S)-3-(4-{{(4-({[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)-2-{{(2S)-2-{{[dibenzo[b,d]furan-4-yl]carbonyl}amino}-4-methylpentanoyl}amino}propanoic acid;  
(2S)-3-(4-{{(4-({[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl)carbonyl}oxy}phenyl)-2-{{(2S)-4-methyl-2-{{[2-{{[3-(1-piperidinyl)carbonyl}-2-naphthyl]oxy}acetyl]amino}pentanoyl}amino}propanoic acid;  
(2S)-2-{{(2S)-2-{{[2-(Tert-butyl)phenoxy]acetyl]amino}-4-methyl pentanoyl}amino}-3-{{4-{{(4-{{[2-cyclohexyl]acetyl}amino}-1-piperidinyl)carbonyl}oxy}phenyl}propanoic acid;  
(2S)-2-{{(2S)-2-{{[2-[2-(Tert-butyl)phenoxy]acetyl]amino}-4-methyl pentanoyl}amino}-3-{{4-{{(4-{{[2,2-dicyclohexyl]acetyl}amino}-1-piperidinyl)carbonyl}oxy}phenyl}propanoic acid;  
(2S)-2-{{(2S)-4-Methyl-2-{{[2-(2-methylphenoxy)acetyl]amino} pentanoyl}amino}-3-{{4-{{(4-{{[2-phenyl]acetyl}amino}-1-piperidinyl)carbonyl} oxy}phenyl}propanoic acid;  
(2S)-2-{{(2S)-2-{{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl}amino}-3-{{4-{{(4-{{[2-phenyl]acetyl}amino}-1-piperidinyl)carbonyl}oxy}phenyl}propanoic acid;  
(2S)-3-{{4-{{(4-{{[2-Cyclohexyl]acetyl}amino}-1-piperidinyl)carbonyl} oxy}phenyl}-2-{{(2S)-2-{{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl}amino}propanoic acid;  
and salts and solvates thereof.

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

Claim 40 (Currently amended): A compound selected from the group consisting of formula (I) which is:

(2S)-2-[((2S)-2-{[2-(2-Iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[4-morpholinylcarbonyl]oxy]phenyl}propanoic acid;  
(2S)-2-{[(2S)-2-{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl)amino}-3-{4-[4-morpholinylcarbonyl]oxy]phenyl}propanoic acid;  
(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-{(2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;  
(2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[4-morpholinylcarbonyl]oxy]phenyl}propanoic acid;  
(2S)-2-{[(2S)-2-{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl)amino}-3-{4-[(4-(2-phenylacetyl)amino)-1-piperidinyl]carbonyl} oxy] phenyl}propanoic acid;  
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-{(2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;  
(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;  
(2S)-2-{[(2S)-2-{(2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl)amino}-3-[4-((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy]phenyl] propanoic acid;  
(2S)-2-((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl)amino)-3-[4-((4-(2-furoyl)-1-piperazinyl)carbonyl)oxy]phenyl] propanoic acid;  
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[(2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid;  
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino)propanoic acid;  
and salts and solvates thereof.

Claim 41 (Currently amended): A compound selected from the group consisting of formula (I) which is:

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

(2S)-3-(4-{{(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl}-2-[(2S)-4-methyl-2-{{(2-  
(2-methylphenoxy)acetyl]amino}pentanoyl]amino]propanoic acid;  
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]oxy}phenyl]-2-{{(2S)-2-  
[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl]amino} propanoic acid;  
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]oxy}phenyl]-2-{{(2S)-2-{{(2-  
[2-(tert-butyl)phenoxy]acetyl]amino)-4-methylpentanoyl]amino} propanoic acid;  
(2S)-2-[(2S)-4-Methyl-2-{{(2-(2-methylphenoxy)acetyl]amino} pentanoyl]amino]-3-  
{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;  
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]oxy}phenyl]-2-{{(2S)-2-{{(2-  
(2-benzoylphenoxy)acetyl]amino}-4-methylpentanoyl]amino} propanoic acid;  
(2S)-2-{{(2S)-2-{{(2-[4-(Aminocarbonyl)phenoxy]acetyl]amino)-4-  
methylpentanoyl]amino}-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl]oxy}  
phenyl]propanoic acid;  
and salts and solvates thereof.

Claim 42 (Currently amended): A compound of formula (I) which is:

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]oxy}phenyl]-2-[(2S)-4-  
methyl-2-{{(2-(2-methylphenoxy)acetyl]amino}pentanoyl]amino] propanoic acid or a  
salt or solvate thereof.

Claim 43 (Currently amended): A compound of formula (I) according to claim 42

which is:

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl]oxy}phenyl]-2-[(2S)-4-  
methyl-2-{{(2-(2-methylphenoxy)acetyl]amino}pentanoyl]amino] propanoic acid  
potassium salt or a solvate thereof.

Claim 44 (Previously presented): A pharmaceutical composition comprising a  
compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt  
or solvate thereof in admixture with one or more pharmaceutically acceptable diluents  
or carriers.


Serial No. 09/868,395  
 Attorney Docket No. PG3612USw

**Claim 45 (Previously presented):** A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination together with a long acting  $\beta_2$  adrenergic receptor agonist.

**Claims 46 and 47 (Cancelled)**

**Claim 48 (Currently amended):** A process for preparation of a compound of formula (I) as defined in according to claim 29 which comprises:

(a) hydrolyzing hydrolysis of a carboxylic acid ester of formula (II)



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or

(b) deprotecting a compound according to claim 29 of formula (I) which is protected.

**Claims 49-55 (Cancelled)**

**Claim 56 (New):** A method of inhibiting eosinophil infiltration into the lungs of a patient comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.

**Claim 57 (New):** A method of antagonizing VLA-4 comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.